Seroatlas · Human Serome Atlas

FANCG

Fanconi anemia group G protein

Also known as: FAG, FANCG_HUMAN, XRCC9

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O15287
Gene
FANCG
Ensembl
ENSG00000221829
Chromosome
9
Canonical length
622 aa
Protein class
Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins
Subcellular location
Nuclear speckles

OverviewNCBI Gene

The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group G. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

622 residues, UniProt reviewed canonical sequence.

>O15287|FANCG
     1  MSRQTTSVGS SCLDLWREKN DRLVRQAKVA QNSGLTLRRQ QLAQDALEGL RGLLHSLQGL
    61  PAAVPVLPLE LTVTCNFIIL RASLAQGFTE DQAQDIQRSL ERVLETQEQQ GPRLEQGLRE
   121  LWDSVLRASC LLPELLSALH RLVGLQAALW LSADRLGDLA LLLETLNGSQ SGASKDLLLL
   181  LKTWSPPAEE LDAPLTLQDA QGLKDVLLTA FAYRQGLQEL ITGNPDKALS SLHEAASGLC
   241  PRPVLVQVYT ALGSCHRKMG NPQRALLYLV AALKEGSAWG PPLLEASRLY QQLGDTTAEL
   301  ESLELLVEAL NVPCSSKAPQ FLIEVELLLP PPDLASPLHC GTQSQTKHIL ASRCLQTGRA
   361  GDAAEHYLDL LALLLDSSEP RFSPPPSPPG PCMPEVFLEA AVALIQAGRA QDALTLCEEL
   421  LSRTSSLLPK MSRLWEDARK GTKELPYCPL WVSATHLLQG QAWVQLGAQK VAISEFSRCL
   481  ELLFRATPEE KEQGAAFNCE QGCKSDAALQ QLRAAALISR GLEWVASGQD TKALQDFLLS
   541  VQMCPGNRDT YFHLLQTLKR LDRRDEATAL WWRLEAQTKG SHEDALWSLP LYLESYLSWI
   601  RPSDRDAFLE EFRTSLPKSC DL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FANCG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.28
Highest tissue expression
8.8 nTPM

Expression across tissuesHPA

Tissue

  • thymus: 8.8 nTPM
  • cerebellum: 8.5 nTPM
  • bone marrow: 6.8 nTPM
  • pancreas: 6.4 nTPM
  • testis: 6.1 nTPM
  • esophagus: 5.9 nTPM

Single-cell type

  • differentiating spermatogonia: 13 nCPM
  • early primary spermatocytes: 12 nCPM
  • megakaryocyte progenitors: 8.4 nCPM
  • erythrocyte progenitors: 6.1 nCPM
  • extravillous trophoblasts: 5.8 nCPM
  • undifferentiated spermatogonia: 5.2 nCPM

Immune cell

  • basophil: 10 nTPM
  • T-reg: 7.7 nTPM
  • NK-cell: 6.1 nTPM
  • eosinophil: 5.5 nTPM
  • gdT-cell: 5.1 nTPM
  • memory B-cell: 4.7 nTPM

Brain region

  • choroid plexus: 2.4 nTPM
  • midbrain: 2.4 nTPM
  • amygdala: 2.3 nTPM
  • cerebellum: 2.3 nTPM
  • cerebral cortex: 2.3 nTPM
  • medulla oblongata: 2.3 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about FANCG.

Disease | AllUniProt

Conditions FANCG is implicated in, by any mechanism.

  • Fanconi anemia complementation group G (FANCG) MIM:614082

Disease | GeneticClinVar

214 pathogenic / likely-pathogenic of 1,511 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.09
gnomAD pLI
0
gnomAD missense Z
0.24
DepMap mean gene effect
-0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FANCG in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FANCG as an antibody target. Whether an autoantibody or antibody against FANCG could matter depends on whether native FANCG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FANCG is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label FANCG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/FANCG. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...